The body’s response to allergic asthma also helps protect against COVID-19

Scientists are discovering a surprising bright side for some people with asthma: They are less susceptible to COVID-19.

The very same immune system proteins that trigger excess mucus production and closing of airways in people with allergic asthma may erect a shield around vulnerable airway cells, researchers report in the April 19 Proceedings of the National Academy of Sciences. The finding helps explain why people with allergic asthma seem to be less susceptible to COVID-19 than those with related lung ailments, and could eventually lead to new treatments for the coronavirus.    

Asthma is a breathing disorder characterized by airway inflammation. The result is coughing, wheezing and shortness of breath. About 8% of people in the United States have asthma, with about 60% of them having allergic asthma. Allergic asthma symptoms are triggered by allergens such as pollen or pet dander. Other types of asthma can be set off by exercise, weather or breathing in irritants such as strong perfumes, cleaning fumes or air pollution.

Usually, asthma is bad news when it comes to colds and flu. At the start of the pandemic, most experts predicted that coronavirus infections and asthma would be a dangerous mix, says Luke Bonser, a cell biologist at the University of California, San Francisco, who was not involved in the study. And that is true for people whose asthma is not triggered by allergies and those with related lung disorders like chronic obstructive pulmonary disease, or COPD. Those conditions put people at high risk for severe COVID-19.

But as the pandemic progressed, researchers noticed that people with allergic asthma weren’t developing severe COVID-19 as often as expected. Here’s a look at why that may be.

Protein protection

What sets allergic asthma apart from other types of asthma and COPD is a protein called interleukin-13, or IL-13.

Usually, IL-13 helps the body fight off parasites such as worms. Certain T cells pump out the protein, and the body responds by churning out sticky mucus and constricting airways. This traps the worms, holding them in place until other immune system cells can come in for the kill.

“In the case of [allergic] asthma, the body is making a mistake. It’s mistaking a harmless substance, like pollen, for a worm,” says Burton Dickey, a pulmonologist at M.D. Anderson Cancer Center in Houston who was not involved in the study.  

But it wasn’t clear how IL-13 was protecting people with allergic asthma from SARS-CoV-2, the coronavirus that causes COVID-19. To find out, pathophysiologist Camille Ehre of the University of North Carolina School of Medicine in Chapel Hill and colleagues grew cells from the lining of the airways from six lung donors. Some of the cells were treated with IL-13 to mimic allergic asthma. Then the researchers infected some of the cells with SARS-CoV-2.

Lawn trouble

Next on the list of to-dos was to compare how cells that haven’t been treated with IL-13 behave when healthy and when infected with the coronavirus.

Uninfected cells grew in lawns resembling lush grasslands, where the tufts of waving fronds are actually hairlike protrusions called cilia, which grow from the tops of airway-lining cells, the team confirmed. Cilia’s motions help move mucus, and anything stuck in the mucus, out of the lungs.

Morrison and Edwards et al., PNAS 2022 (CC BY 4.0)

Healthy human cells (labeled pink) from the lining of airways grow in “lawns” laced with some mucus (green) in this colorized
electron micrograph.

Cells infected with the coronavirus looked much different. The lush lawn was now slathered in mucus, and bald spots appeared as infected cells died. The doomed cells get squeezed out of the lawn of cilia and inflate like a balloon. The inflation happens partly because chambers called vacuoles inside the infected cells get clogged with viruses. “It’s just filled with viruses, and then it gets kicked out of the club and it blows up and releases all these viruses,” Dickey says.

Morrison and Edwards et al., PNAS 2022 (CC BY 4.0)

During a coronavirus infection, dying airway-lining cells (labeled blue) are ejected from areas of healthy cells (pink) slathered
in mucus (green) in this colorized electron micrograph.

But not all the cells in the infected lawn were affected equally. Looking at the cells from the side, researchers could see that cells sporting cilia were infected with the coronavirus. But mucus-producing cells called goblet cells, which don’t have cilia, were rarely infected. That may be because a protein called ACE2 decorates the surface of ciliated cells far more often than it does goblet cells. ACE2 is the protein that the coronavirus uses as a door into cells.

Morrison and Edwards et al., PNAS 2022 (CC BY 4.0)

Airway cells topped by hairlike cilia (seen from the side) are more likely to be infected with the coronavirus (viral RNA labeled
blue) than cells that don’t have cilia.

A sticky solution

When researchers doused the cells with IL-13 before adding the coronavirus, the results were strikingly different.

The lawn of waving cilia atop the treated cells was mostly intact, with far fewer balloons of dying cells rising above the surface. But the fronds didn’t wave as vigorously as in untreated cells. That’s because IL-13 reduces cilia beating, the researchers found.  Less active cilia could mean that virus-laden mucus sticks around longer. “That can be a double-edged sword inside the lungs because you want to clear the mucus, but you don’t want to spread it around,” Ehre says.

Morrison and Edwards et al., PNAS 2022 (CC BY 4.0)

Left: Untreated airway cells, 96 hours after a coronavirus infection. Right: Airway cells treated with the immune system protein interleukin-13, 96 hours after a coronavirus infection.

Counting cells under the microscope, the researchers saw that far fewer of the infected cells treated with IL-3 got the heave-ho. Whereas the untreated cells had ejected about 700 of their own by about four days after infection, only about 100 treated cells had gotten kicked out. The images showed that IL-13 really was protecting cells from infection. But how was still an unanswered question.

One thing that IL-13 does is stimulate airway-lining cells to churn out a type of sticky mucus that can trap viruses before they can infect cells. The team found that untreated cells released a burst of the mucus shortly after being infected with the coronavirus, depleting stores of the sticky stuff. But cells treated with IL-13 were still well-stocked with mucus.

Morrison and Edwards et al., PNAS 2022 (CC BY 4.0)

Left: Side view of untreated airway cells (DNA labeled blue) infected with SARS-CoV-2 (green), which quickly deplete stores of mucus (red). Right: Side view of airway cells (DNA labeled blue) treated with the immune system protein interleukin-13. These cells make lots of mucus (red) and are rarely infected by SARS-CoV-2 (green).

All that extra mucus from the treated cells could ensnare viruses and expel them from the lungs before much damage is done. But people with nonallergic asthma and COPD make plenty of mucus too, and they aren’t protected from the virus. So Ehre and colleagues stripped away the mucus to see how the airway cells fared without this phlegmy trap.

Even without the mucus, IL-13 was still protective.

Barricading the doors

Examining patterns of gene activity, the team found that IL-13 was also causing cells to make less ACE2, the protein that SARS-CoV-2 commandeers as a gateway into cells. “It makes it much harder for the virus to find its door to enter the cells,” Ehre says.

That result agrees with previous findings from Bonser and colleagues. “Being able to replicate the same data in several different studies, that’s great,” he says. And the new study looks more closely into IL-13’s protective mechanism than previous research did.

Cells treated with IL-13 also turn down the activity of genes involved in making protein-producing factories called ribosomes, the researchers discovered. That may limit viral replication in cells. But some genes’ activity was also turned way up. That includes several genes involved in making keratan sulfate, a long, sugar-studded protein that is found in cartilage and the eyes’ corneas. “It’s there in the body to make a shield,” Ehre says.

That seems to be what it is doing for airway cells too. A thick layer of keratan sulfate developed on top of cells treated with IL-13, armoring them against a coronavirus infection.

Morrison and Edwards et al., PNAS 2022 (CC BY 4.0)

Left: Side view of untreated airway cells (DNA labeled blue). These cells make little keratan sulfate (pink) and are easily infected by SARS-CoV-2 (green). Right: Side view of airway cells treated with IL-13 (DNA labeled blue), which shield themselves from the coronavirus (green) with a thick layer of keratan sulfate (pink).

Which of these protective mechanisms is most important, or if it’s a combination of all of them, is one of the many things left to explore, Ehre says. “This paper is not the final paper that figures everything out. There is way more work to do.”

Knowing even more details about how IL-13 works to protect against the coronavirus could lead to new treatments, Bonser says. But IL-13 itself probably will not be used as a drug because of the inflammation, excess mucus, cough and shortness of breath it triggers.

Unfortunately, the extra protection doesn’t mean that people with allergic asthma don’t have to be concerned about getting COVID-19, Dickey says. “People with asthma have had very bad outcomes. This is not a virus you want to take chances with,” he says. But it’s OK to bask on the bright side a little. “It’s not fun to have asthma, so you have to be grateful for every rare occasion where it does something useful.”

This story was originally published by Science News, a nonprofit independent news organization.